Comparison of Intravitreal Bevacizumab and Ranibizumab Treatment for Diabetic Macular Edema

Basit Öğe Kaydı
dc.contributor.authorOzturk, Banu Turgut
dc.contributor.authorKerimoglu, Hurkan
dc.contributor.authorBozkurt, Banu
dc.contributor.authorOkudan, Suleyman
dc.date.accessioned2020-03-26T18:13:59Z
dc.date.available2020-03-26T18:13:59Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAim: The aim of this study was to compare the effects of bevacizumab and ranibizumab on visual function and macular thickness in patients with diabetic macular edema (DME). Methods: The data of diabetic patients who had been treated with bevacizumab for DME were reviewed. Those patients who received 1 injection of intravitreal bevacizumab and ranibizumab with at least 6-month interval were considered for enrollment. The best-corrected visual acuity (BCVA) assesment with Early Treatment Diabetic Retinopathy Study (ETDRS) chart and central subfield macular thickness (CSMT) measurement using optical coherence tomography-3 before and after the injections were recorded as outcome measures. Results: The study included 29 eyes of 29 patients with a mean age of 56.18 +/- 3.07 years. The median BCVA was 59 ETDRS letters and the median CSMT was 411 mu m preceeding the bevacizumab injection. At the 4th-6th week control after the injection, median BCVA increased to 61.50 ETDRS letters and the median CSMT decreased to 373 mu m. This change in BCVA and CSMT was found to be statistically significant (P = 0.029 and P = 0.011, respectively). The mean interval between bevacizumab and ranibizumab treatment was 9.54 +/- 2.64 months. Ranibizumab treatment increased the median BCVA from 53 to 66 ETDRS letters and decreased the median CSMT from 428 mu m to a level of 279 mu m, which were statistically significant (P < 0.001 and P < 0.001, respectively). The median change in BCVA was 4.5 ETDRS letters in the bevacizumab group and 6 ETDRS letters in the ranibizumab group (P = 0.58), whereas the median changes in CSMT were 41 and 100 mu m after bevacizumab and ranibizumab injections, respectively (P = 0.005). Conclusions: Bevacizumab and ranibizumab are both effective antivascular endothelial growth factor drugs preferred in the treatment of DME. Our comparison of both therapies on the same patients suggested that the effect on BCVA was not statistically different, but ranibizumab provided more decrease in CSMT.en_US
dc.identifier.doi10.1089/jop.2010.0195en_US
dc.identifier.endpage377en_US
dc.identifier.issn1080-7683en_US
dc.identifier.issn1557-7732en_US
dc.identifier.issue4en_US
dc.identifier.pmid21631366en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage373en_US
dc.identifier.urihttps://dx.doi.org/10.1089/jop.2010.0195
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26258
dc.identifier.volume27en_US
dc.identifier.wosWOS:000293388900011en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMARY ANN LIEBERT, INCen_US
dc.relation.ispartofJOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleComparison of Intravitreal Bevacizumab and Ranibizumab Treatment for Diabetic Macular Edemaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu